Angelo Pirozzi, Research Fellow at Mayo Clinic, shared on X:
“Update on FIGHT-202
145 patients with pretreated advanced CCA and FGFR2 alterations received pemigatinib
Median follow-up 45 mos For FGFR2 fusions:
- ORR 37%
- mDOR 9.1 mos
- mPFS 7.0 mos
- mOS 17.5 mos
- 10.2% TEAEs led to discontinuation.“
Read further.
Source: Angelo Pirozzi/X